476 related articles for article (PubMed ID: 31065692)
1. Aberrant alternative splicing in breast cancer.
Yang Q; Zhao J; Zhang W; Chen D; Wang Y
J Mol Cell Biol; 2019 Oct; 11(10):920-929. PubMed ID: 31065692
[TBL] [Abstract][Full Text] [Related]
2. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing in cancers: From aberrant regulation to new therapeutics.
Song X; Zeng Z; Wei H; Wang Z
Semin Cell Dev Biol; 2018 Mar; 75():13-22. PubMed ID: 28919308
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of splicing factors and breast cancer development.
Silipo M; Gautrey H; Tyson-Capper A
J Mol Cell Biol; 2015 Oct; 7(5):388-401. PubMed ID: 25948865
[TBL] [Abstract][Full Text] [Related]
5. Widespread Alternative Splicing Changes in Metastatic Breast Cancer Cells.
Oh J; Pradella D; Shao C; Li H; Choi N; Ha J; Ruggiero S; Fu XD; Zheng X; Ghigna C; Shen H
Cells; 2021 Apr; 10(4):. PubMed ID: 33918758
[TBL] [Abstract][Full Text] [Related]
6. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
7. Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
Vadlamudi Y; Dey DK; Kang SC
Curr Cancer Drug Targets; 2020; 20(9):654-665. PubMed ID: 32564755
[TBL] [Abstract][Full Text] [Related]
8. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
9. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
10. From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.
Tian N; Li J; Shi J; Sui G
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257090
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Wang L; Wang Y; Su B; Yu P; He J; Meng L; Xiao Q; Sun J; Zhou K; Xue Y; Tan J
Sci Rep; 2020 Oct; 10(1):16504. PubMed ID: 33020551
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of splicing in cancer.
Lee SC; Abdel-Wahab O
Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
[TBL] [Abstract][Full Text] [Related]
13. A combinatorially regulated RNA splicing signature predicts breast cancer EMT states and patient survival.
Qiu Y; Lyu J; Dunlap M; Harvey SE; Cheng C
RNA; 2020 Sep; 26(9):1257-1267. PubMed ID: 32467311
[TBL] [Abstract][Full Text] [Related]
14. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
15. Splicing Regulators and Their Roles in Cancer Biology and Therapy.
da Silva MR; Moreira GA; Gonçalves da Silva RA; de Almeida Alves Barbosa É; Pais Siqueira R; Teixera RR; Almeida MR; Silva Júnior A; Fietto JL; Bressan GC
Biomed Res Int; 2015; 2015():150514. PubMed ID: 26273588
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing: an emerging topic in molecular and clinical oncology.
Pajares MJ; Ezponda T; Catena R; Calvo A; Pio R; Montuenga LM
Lancet Oncol; 2007 Apr; 8(4):349-57. PubMed ID: 17395108
[TBL] [Abstract][Full Text] [Related]
17. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
Bessa C; Matos P; Jordan P; Gonçalves V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
[TBL] [Abstract][Full Text] [Related]
18. Misregulation of pre-mRNA alternative splicing in cancer.
Zhang J; Manley JL
Cancer Discov; 2013 Nov; 3(11):1228-37. PubMed ID: 24145039
[TBL] [Abstract][Full Text] [Related]
19. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes.
Dowhan DH; Harrison MJ; Eriksson NA; Bailey P; Pearen MA; Fuller PJ; Funder JW; Simpson ER; Leedman PJ; Tilley WD; Brown MA; Clarke CL; Muscat GE
Endocr Relat Cancer; 2012 Aug; 19(4):509-26. PubMed ID: 22673335
[TBL] [Abstract][Full Text] [Related]
20. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
